The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Abstract
Purpose: To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. Methods: An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines previously published by this group in the Journal of Clinical Oncology in 1998. MEDLINE searches were performed and the relevant literature published since 1998 was reviewed by all panel members. The treatment recommendations and algorithm were revised by panel consensus. Results: A recent review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication. Loperamide remains the standard therapy for uncomplicated cases. However, the revised guidelines reflect the need for recognition of the early warning signs of complicated cases of diarrhea and the need for early and aggressive management, including the addition of antibiotics. Management of radiation-induced diarrhea is similar but may not require hospitalization, and chronic low- to intermediate-grade symptoms can be managed with continued loperamide. Conclusion: With vigilant monitoring and aggressive therapy for cancer treatment-induced diarrhea, particularly in patients with early warning signs of severe complications, morbidity and mortality may be reduced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Self-citationRubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.600 · Cited by 389
Self-citationLeichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., & Mangalik, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1303 · Cited by 359
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea
Abigerges, D., Armand, J.-P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., & Gandia, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.446 · Cited by 248
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler, S., Benson, A. B., Engelking, C., Catalano, R., Field, M., Kornblau, S. M., Mitchell, E., Rubin, J., Trotta, P., & Vokes, E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3169 · Cited by 164
Self-citationArbuckle, R. B., Huber, S. L., & Zacker, C. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-250 · Cited by 100
Takeda, Y., Kobayashi, K., Akiyama, Y., Soma, T., Handa, S., Kudoh, S., & Kudo, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200102)9999:9999<::aid-ijc1179>3.0.co;2-3 · Cited by 81
Lenfers, B., Loeffler, T. M., Droege, C., & Hausamen, T.-U. (1999) · Annals of Oncology · doi:10.1023/a:1008390308416 · Cited by 76
Control of irinotecan-induced diarrhea by octreotide after loperamide failure
Barbounis, V., Koumakis, G., Vassilomanolakis, M., Demiri, M., & Efremidis, A. P. (2001) · Supportive Care in Cancer · doi:10.1007/s005200000220 · Cited by 74
Martenson, J. A., Hyland, G., Moertel, C. G., Mailliard, J. A., O'Fallon, J. R., Collins, R. T., Morton, R. F., Tewfik, H. H., Moore, R. L., Frank, A. R., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(96)00016-8 · Cited by 72
Self-citationKılıç, D., Egehan, Î., Özeni̇rler, S., & Dursun, A. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00254-1 · Cited by 70
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy
Gebbia, V., Carreca, I. U., Testa, A., Valenza, R., Curto, G., Cannata, G. E., Borsellino, N., Latteri, M. A., Cipolla, C., Florena, M., et al. (1993) · Anti-Cancer Drugs · doi:10.1097/00001813-199308000-00004 · Cited by 57
Merrouche, Y., Extra, J.-M., Abigerges, D., Bugat, R., Catimel, G., Suc, E., Marty, M. E., Herait, P., Mahjoubi, M., & Armand, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1080 · Cited by 55
Kneebone, A. B., Mameghan, H., Bolin, T. D., Berry, M. P., Turner, S., Kearsley, J. H., Graham, P., Fisher, R., & Delaney, G. P. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01660-1 · Cited by 50
Wadler, S., Haynes, H., & Wiernik, P. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.222 · Cited by 43
Self-citationOctreotide Acetate in the Treatment of Fluorouracil‐Induced Diarrhea
Goumas, P. D., Naxakis, S. S., Christopoulou, A. N., Chrysanthopoulos, C. J., Nikolopoulou, V., & Kalofonos, H. P. (1998) · The Oncologist · doi:10.1634/theoncologist.3-1-50 · Cited by 41
Cascinu, S., Bichisao, E., Amadori, D., Silingardi, V., Giordani, P., Sansoni, E., Luppi, G., Catalano, V., Agostinelli, R., & Catalano, G. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900085 · Cited by 29
Ychou, M., Douillard, J.-Y., Rougier, P. R., Adenis, A., Mousseau, M., Dufour, P., Wendling, J. L., Bürki, F., Mignard, D., & Marty, M. E. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200004000-00008 · Cited by 27
Meropol, N. J., Blumenson, L. E., & Creaven, P. J. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199804000-00007 · Cited by 15
Cited by
Stewart, F. A., Akleyev, A. V., Hauer-Jensen, M., Hendry, J. H., Kleiman, N. J., MacVittie, T. J., Aleman, B. M., Edgar, A. B., Mabuchi, K., Muirhead, C. R., et al. (2012) · Annals of the ICRP · doi:10.1016/j.icrp.2012.02.001 · Cited by 1,604
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
“The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization [Benson et al. 2004; Maroun et al. 2007].”
BackgroundMethodInfluentialTouchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., & de La Cochetière, M. F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12878 · Cited by 425
Rugo, H. S., Bardia, A., Marmé, F., Cortes, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Pardo, P. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01002 · Cited by 316
Metadata
- Authors
- Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., & Wadler, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2918-2926
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097257602
- Cited by
- 631
- References
- 24
- FWCI
- 18.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.